Skip to content

DMT research published in 2023

56 studies whose primary subject is DMT were published in 2023, up from 34 in 2022. Newest first. Back to the DMT overview

Studies

Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans

Biomedicine & Pharmacotherapy December 31, 2023 David Fabregat-Safont, Alex Gomez-Gomez, Francisco Madrid-Gambin et al.

Psychedelics are classical hallucinogen drugs that induce a marked altered state of consciousness. In recent years, there has been renewed attention to the possible use of classical psychedelics for the treatment of certain mental health disorders. However, further investigation to better understand their biological effects in humans, their mechanism of action, and their metabolism in humans is...

Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie December 31, 2023 Francisco Madrid-Gambin, David Fabregat-Safont, Alex Gomez-Gomez et al. 12 citations

Psychedelics are classical hallucinogen drugs that induce a marked altered state of consciousness. In recent years, there has been renewed attention to the possible use of classical psychedelics for the treatment of certain mental health disorders. However, further investigation to better understand their biological effects in humans, their mechanism of action, and their metabolism in humans is...

Serotonergic psychedelic 5-MeO-DMT alters plasticity-related gene expression and generates anxiolytic effects in stressed mice

Research Square December 28, 2023 Margareth Nogueira, Daiane C Ferreira Golbert, Richardson Menezes et al. 2 citations preprint

Abstract Serotonergic psychedelics have potential therapeutic effects in treating anxiety and mood disorders, often after a single dose, and are suggested to have plasticity-inducing action. One lesser studied psychedelic, the 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT), is suggested to have anxiolytic effects yet a comprehensive mechanism of action is still lacking. Here, we investigated the...

5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?

Psychopharmacology December 11, 2023 Haley Maria Dourron, Charles D. Nichols, Otto Simonsson et al. 23 citations

5-MeO-DMT is a tryptamine being developed as a potential antidepressant that may display a distinct therapeutic mechanism due to its unique pharmacology and subjective effects compared to typical psychedelics. In this article, we parallel the relatively distinct phenomenology and behavioral effects of the acute and post-acute effects of 5-MeO-DMT to those induced by epileptiform activity,...

DOI: 10.1007/s00213-023-06517-1 (opens in new tab) Full text (opens in new tab) 5-ht1a receptors Flashbacks Seizures Psychedelics hallucinogens +7

N, N-dimethyltryptamine forms oxygenated metabolites via CYP2D6 - an in vitro investigation.

Xenobiotica December 1, 2023 Emma Eckernäs, Alicia Macan-Schönleben, Moa Andresen-Bergström et al. 6 citations

N, N-dimethyltryptamine (DMT) is a psychedelic compound that has shown potential in the treatment of depression. Aside from the primary role of monoamine oxidase A (MAO-A) in DMT metabolism, the metabolic pathways are poorly understood. Increasing this understanding is an essential aspect of ensuring safe and efficacious use of DMT.This work aimed to investigate the cytochrome 450 (CYP)...

DOI: 10.1080/00498254.2023.2278488 (opens in new tab) Full text (opens in new tab) N n-dimethyltryptamine Cytochrome p450 Human liver microsomes In vitro metabolism +6

The possible place for psychedelics in pharmacotherapy of mental disorders.

Pharmacological Reports December 1, 2023 Adam Wojtas 10 citations

Since its emergence in the 1960s, the serotonergic theory of depression bore fruit in the discovery of a plethora of antidepressant drugs affecting the lives of millions of patients. While crucial in the history of drug development, recent studies undermine the effectiveness of currently used antidepressant drugs in comparison to placebo, emphasizing the long time it takes to initiate the...

Ayahuasca: A review of historical, pharmacological, and therapeutic aspects.

Psychiatry and Clinical Neurosciences Reports December 1, 2023 Simon Ruffell, Max Crosland-Wood, Rob Palmer et al. 37 citations

Ayahuasca is a psychedelic plant brew originating from the Amazon rainforest. It is formed from two basic components, the Banisteriopsis caapi vine and a plant containing the potent psychedelic dimethyltryptamine (DMT), usually Psychotria viridis. Here we review the history of ayahuasca and describe recent work on its pharmacology, phenomenological responses, and clinical applications. There...

5-MeO-DMT for post-traumatic stress disorder: a real-world longitudinal case study

Frontiers in Psychiatry November 23, 2023 Anya Ragnhildstveit, Ryan Khan, Paul Seli et al. 17 citations

Psychedelic therapy is, arguably, the next frontier in psychiatry. It offers a radical alternative to longstanding, mainstays of treatment, while exciting a paradigm shift in translational science and drug discovery. There is particular interest in 5-methoxy- N,N -dimethyltryptamine (5-MeO-DMT)—a serotonergic psychedelic—as a novel, fast-acting therapeutic. Yet, few studies have directly...

DOI: 10.3389/fpsyt.2023.1271152 (opens in new tab) Adverse effect Psychopathology Clinical psychology

A mechanistic insight for the biosynthesis of N,N-dimethyltryptamine: An ONIOM theoretical approach.

Biochemical and Biophysical Research Communications October 20, 2023 Lucas Pinheiro Coutinho, Sérgio Ruschi Bergamachi Silva, Pedro de Lima-Neto et al. 3 citations

Psychoactive natural products are potent serotonergic agonists capable of modulating brain functions such as memory and cognition. These substances have shown therapeutic potential for treating various mental disorders. The fact that N,N-dimethyltryptamine (DMT) is produced endogenously in several plants and animals, including humans, makes it particularly attractive. As an amino acid-derived...

DOI: 10.1016/j.bbrc.2023.08.043 (opens in new tab) Full text (opens in new tab) Mechanism N,N-Dimethyltryptamine DMT Oniom Psychoactives +4

Bedside to bench: the outlook for psychedelic research

Frontiers in Pharmacology October 2, 2023 Victor P Acero, Emily S Cribas, Kevin D Browne et al. 20 citations

There has recently been a resurgence of interest in psychedelic compounds based on studies demonstrating their potential therapeutic applications in treating post-traumatic stress disorder, substance abuse disorders, and treatment-resistant depression. Despite promising efficacy observed in some clinical trials, the full range of biological effects and mechanism(s) of action of these compounds...

THE AYAHUASCA’S PSYCHEDELIC COMPONENT DMT POTENTIATES NEURITOGENESIS IN PC12 CELLS

IBRO Neuroscience Reports October 1, 2023 Mariana Pazos, Ignacio Carrera, Giselle Prunell 1 citation

Ayahuasca is a psychedelic beverage originally from the Amazon rainforest used in different shamanic settings for a variety of medicinal, spiritual, and cultural purposes. It is prepared by decoction of the vine Banisteriopsis caapi, source of β-carboline alkaloids, and, Psychotria viridis containing the classic psychedelic N,N-dimethyltryptamine (DMT). As part of the “renaissance of...

DOI: 10.1016/j.ibneur.2023.08.605 (opens in new tab) Ayahuasca Component thermodynamics Mura Hallucinogen

Optimized infusion rates for N,N-dimethyltryptamine to achieve a target psychedelic intensity based on a modeling and simulation framework.

CPT: Pharmacometrics & Systems Pharmacology October 1, 2023 Emma Eckernäs, Jeroen Koomen, Christopher Timmermann et al. 1 citation

N,N-dimethyltryptamine (DMT) is a psychedelic compound that is being studied as a therapeutic option in various psychiatric disorders. Due to its short half-life, continuous infusion of DMT has been proposed to extend the psychedelic experience and potential therapeutic effects. The primary aim of this work was to design an infusion protocol for DMT based on a desired level of psychedelic...

DOI: 10.1002/psp4.13037 (opens in new tab) Full text (opens in new tab) Psychedelic-therapy DMT-Research Clinical-protocols Pharmacology +1

Molecular Docking, MM-GBSA, and Molecular Dynamics Approach: 5-MeO-DMT Analogues as Potential Antidepressants.

Archives of Razi Institute October 1, 2023 Rajagopal Kalirajan, Khare Rishabh, Jupudi Srikanth et al.

Since depression is a common mental illness affecting an estimated 5% of people worldwide, investigators are encouraged to develop effective antidepressants. According to the monoamine-deficiency hypothesis, the underlying pathophysiology of depression is a deficiency of some neurotransmitters (serotonin, norepinephrine, or dopamine) in the central nervous system. The neurotransmitter serotonin...

Discovery and In Vitro Characterization of SPL028: Deuterated N,N-Dimethyltryptamine.

ACS Medicinal Chemistry Letters September 14, 2023 Marie Layzell, Peter Rands, Meghan Good et al. 6 citations

The psychedelic N,N- dimethyltryptamine (DMT) is in clinical development for the treatment of major depressive disorder. However, when administered via intravenous infusion, its effects are short-lived due to rapid clearance. Here we describe the synthesis of deuterated analogues of DMT with the aim of prolonging the half-life and decreasing the clearance rate while maintaining similar...

DOI: 10.1021/acsmedchemlett.3c00143 (opens in new tab) Full text (opens in new tab) Psychedelics Drug development Mental health treatment Pharmaceutical research

Synthetic studies toward the marine alkaloid convolutindole A, a structurally remarkable derivative of the hallucinogen N,N-Dimethyltryptamine (DMT)

Tetrahedron Letters September 13, 2023 Karen Ichikawa, Jessica C. Neville, Yihan Yu et al. 3 citations

Herein we report the results of a synthetic strategy toward the marine alkaloid convolutindole A, a structurally remarkable derivative of the hallucinogen N,N-dimethyltryptamine (DMT). While attempts to forge an advanced tryptamine intermediate using the Fischer reaction were unsuccessful, an iterative C-H functionalisation strategy proved more fruitful. Subjecting 6-bromoindole to an...

Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico.

The American Journal of Drug and Alcohol Abuse September 3, 2023 Alan Kooi Davis, Yitong Xin, Nathan D. Sepeda et al. 29 citations

Background: Research in psychedelic medicine has focused primarily on civilian populations. Further study is needed to understand whether these treatments are effective for Veteran populations.Objectives: Here, we examine the effectiveness of psychedelic-assisted therapy among trauma-exposed Special Operations Forces Veterans (SOFV) seeking treatment for cognitive and mental health problems in...

Natural psychedelics in the treatment of depression; a review focusing on neurotransmitters.

Fitoterapia September 1, 2023 Samane Jahanabadi, Shayan Amiri, Mehdi Karkeh-Abadi et al. 14 citations

Natural psychedelic compounds are emerging as potential novel therapeutics in psychiatry. This review will discuss how natural psychedelics exert their neurobiological therapeutic effects, and how different neurotransmission systems mediate the effects of these compounds. Further, current therapeutic strategies for depression, and novel mechanism of action of natural psychedelics in the...

Harmonic decomposition of spacetime (HADES) framework characterises the spacetime hierarchy of the DMT brain state

bioRxiv August 21, 2023 Jakub Vohryzek, Joana Cabral, Christopher Timmermann et al. 7 citations preprint

Abstract The human brain is a complex system, whose activity exhibits flexible and continuous reorganisation across space and time. The decomposition of whole-brain recordings into harmonic modes has revealed a repertoire of gradient-like activity patterns associated with distinct brain functions. However, the way these activity patterns are expressed over time with their changes in various...

Major depressive disorder diagnosis from electroencephalogram data and potential treatment with dimethyltryptamine

International Advanced Researches and Engineering Journal August 15, 2023 Sushmit Jahan 1 citation

In recent times, there has been increasing interest in utilizing EEG-based techniques for studying Major Depressive Disorder as a dynamic method. Although it is frequently used for identifying depression, the method is still difficult to interpret. The conventional treatment of MDD involves medications such as Selective Serotonin Reuptake Inhibitors, which often have adverse effects. On the...

A Brief Review on the Potential of Psychedelics for Treating Alzheimer’s Disease and Related Depression

International Journal of Molecular Sciences August 7, 2023 Alexander Pilozzi, Simmie Foster, David Mischoulon et al. 16 citations

Alzheimer’s disease (AD), the most common form of senile dementia, is poised to place an even greater societal and healthcare burden as the population ages. With few treatment options for the symptomatic relief of the disease and its unknown etiopathology, more research into AD is urgently needed. Psychedelic drugs target AD-related psychological pathology and symptoms such as depression. Using...